One limit of all these targeted therapies is the occurrence of insulin resistance and compensatory hyperinsulinemia caused by either direct impairment of the IR function or by growth hormone (GH) increase in response to the reduced IGFs signaling [4, 5]. This evidence concerns the gene GH1 and hyperinsulinism.